Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Pharmaceutical Executive Editorial Staff;

Feature

Article

August 16, 2024

Pharmaceutical Executive

Pharmaceutical Executive: July/August 2024

Volume44

Issue 7/8

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Author(s):

Pharmaceutical Executive Editorial Staff

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Papisut - stock.adobe.com

Follow the links below to read about each product:

Exxua (Fabre-Kramer Pharmaceuticals)

Omvoh (Eli Lilly)

Truqap (AstraZeneca)

Wegovy (Novo Nordisk)

Winrevair (Merck & Co.)

Download Issue PDF

Articles in this issue

Pharmaceutical Executive: July/August 2024 Issue (PDF)

An AI Pulse Check

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

A Promising Option: Exxua

Opening the Door: Omvoh

'Marked’ for Stardom?: Truqap

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Newsletter